Quarterly ResultMay 13, 2026, 04:38 PM
Armata Pharma Q1 Net Loss $115.3M; Secures $25M Loan
AI Summary
Armata Pharmaceuticals reported a net loss of $115.3 million for Q1 2026, significantly wider than the $6.5 million loss in Q1 2025, primarily due to a change in the fair value of its convertible loan. Concurrently, the company secured a $25 million term loan facility from Innoviva Strategic Opportunities LLC, its principal shareholder, to advance its lead therapeutic candidate, AP-SA02. The company also announced positive regulatory developments for AP-SA02, including Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA, and is preparing to initiate a Phase 3 study in H2 2026.
Key Highlights
- Secured a $25 million term loan from Innoviva Strategic Opportunities LLC at 14.0% interest, maturing January 11, 2029.
- Reported Q1 2026 net loss of $115.3 million, or $3.16 per share, compared to a $6.5 million loss ($0.18 per share) in Q1 2025.
- Cash and cash equivalents were $4.8 million as of March 31, 2026, down from $8.7 million on December 31, 2025.
- Q1 2026 grant and award revenue increased to $0.8 million from $0.5 million in Q1 2025.
- Research and development expenses rose to $6.1 million in Q1 2026 from $5.4 million in Q1 2025.
- FDA granted Fast Track and QIDP designations for AP-SA02 for complicated S. aureus bacteremia.
- Preparations are ongoing to advance AP-SA02 into a Phase 3 superiority study in H2 2026.
- Appointed Daniel B. Gilmer, Ph.D. to the Board of Directors.